A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Latest Information Update: 07 Jun 2023
At a glance
- Drugs Belumosudil (Primary)
- Indications Diffuse scleroderma
- Focus Therapeutic Use
- Acronyms dcSSC
- Sponsors Kadmon Holdings; Sanofi
- 20 Mar 2023 Status changed from completed to discontinued.
- 05 Jan 2023 Status changed from active, no longer recruiting to completed.
- 08 Aug 2022 Planned End Date changed from 1 Feb 2023 to 21 Dec 2022.